(MD) Mednax - Ratings and Ratios

Pediatrix Medical Group, Inc. (NYSE: MD), formerly known as MEDNAX, Inc., is a leading provider of specialized pediatric and maternal-fetal healthcare services in the United States. Founded in 1979 and headquartered in Sunrise, Florida, the company operates through its subsidiaries to deliver critical care services across multiple clinical settings. Its core offerings include neonatal care for premature or critically ill newborns, maternal-fetal medicine for high-risk pregnancies, and a range of pediatric subspecialty services. The company employs a multidisciplinary team of neonatologists, pediatric intensivists, maternal-fetal medicine specialists, and other healthcare professionals to provide comprehensive care in hospitals, nurseries, and outpatient clinics. Pediatrix Medical Group also offers newborn hearing screening programs and support services in pediatric emergency rooms, labor and delivery units, and other hospital departments. The companys services are designed to address the complex medical needs of newborns, expectant mothers, and children, leveraging advanced clinical protocols and technology to improve patient outcomes.

From a technical perspective, Pediatrix Medical Groups stock (NYSE: MD) has shown stable price action, with its 20-day moving average at 12.91 closely aligning with its last price of 12.94. The 50-day moving average at 13.88 and 200-day moving average at 12.82 suggest a slight downtrend over the medium term. The average true range (ATR) of 0.59 indicates moderate volatility. On the fundamental side, the companys market cap of $1.1 billion reflects its established presence in the healthcare services sector. The forward P/E of 8.24 points to potential undervaluation, though the negative return on equity (-12.95) raises concerns about profitability. The price-to-book ratio of 1.44 and price-to-sales ratio of 0.55 suggest the stock may offer value for investors willing to overlook short-term financial challenges. Overall, Pediatrix Medical Groups stock is positioned for stability with upside potential, supported by its essential healthcare services and attractive valuations.